Work

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Year: 2017

Type: article

Study design: Case Report

Abstract: Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2017007526

Authors: Larisa Broglie, Lauren Pommert, Sridhar Rao, Monica Thakar, Rachel Phelan, David Margolis, Julie Talano

Institutions: Children's Hospital of Wisconsin, Medical College of Wisconsin

Language: English

Topic: Autoimmune and Inflammatory Disorders Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funders: National Institutes of Health, National Center for Advancing Translational Sciences

Awards: J. NRSA Training Core, G7413735267, Clinical and Translational Science Award

OpenAlex ID: W2750546050

FWCI: 13.28

Cites: 22

Cited by: 129

Related to: 10